Endocrine Pharmacology Practice Questions

Q: What is the mechanism of action of sulfonylureas?

K ATP channel blocker. ***K ATP channel blocker*** - Sulfonylureas bind to the **sulfonylurea receptor 1 (SUR1)** subunit of the **ATP-dependent potassium (KATP) channel** on pancreatic beta cells. - This binding leads to the closure of the KATP channels, causing **depolarization of the beta cell membrane** and subsequent **insulin release**. *Sodium channel blocker* - **Sodium channel blockers** are primarily used in conditions like **cardiac arrhythmias** and **epilepsy**, by stabilizing neuron membranes or altering cardiac action potentials. - They do not directly influence **insulin secretion** from pancreatic beta cells. *Calcium channel blocker* - **Calcium channel blockers** primarily inhibit the influx of calcium ions into cells, affecting **vascular smooth muscle** and **cardiac muscle**, which can influence blood pressure and heart rate. - While calcium influx is crucial for insulin release, sulfonylureas do not directly target these channels. *Chloride channel blocker* - **Chloride channel blockers** are not a primary mechanism of action for antidiabetic medications like sulfonylureas. - Their physiological roles are diverse, including involvement in **epithelial transport** and **cellular excitability**.

Q: Which of the following drugs is known to reduce the risk of both macrovascular and microvascular complications of diabetes mellitus?

Metformin. ***Metformin*** - **Metformin** is the first-line drug for type 2 diabetes with established evidence from the **UKPDS (UK Prospective Diabetes Study)** demonstrating reduction in both **macrovascular** (cardiovascular events, myocardial infarction) and **microvascular** (retinopathy, nephropathy, neuropathy) complications [1] - Particularly effective in **overweight and obese patients**, reducing diabetes-related mortality and all-cause mortality [1] - Mechanisms include decreasing **hepatic glucose production** [3], reducing intestinal glucose absorption, and improving **insulin sensitivity** [1] - Remains the **gold standard** first-line therapy per ADA/EASD guidelines *Acarbose* - Alpha-glucosidase inhibitor that delays carbohydrate absorption in the gut, reducing postprandial glucose excursions [2] - Provides glycemic control but **lacks robust evidence** for significant reduction in both macrovascular and microvascular complications - Primary benefit is in postprandial glucose management, not long-term complication prevention *Repaglinide* - Meglitinide analog that stimulates rapid, short-acting insulin release from pancreatic beta cells [1] - Effective for **postprandial hyperglycemia control** but lacks definitive large-scale trial evidence showing reduction in both macrovascular and microvascular outcomes - No cardiovascular outcome trials demonstrating complication reduction comparable to metformin *Sitagliptin* - DPP-4 inhibitor that enhances incretin hormone activity to improve glycemic control - **TECOS trial** showed cardiovascular safety (non-inferiority) but **not superiority** in reducing macrovascular or microvascular complications - Benefits include weight neutrality and low hypoglycemia risk, but less direct evidence for widespread complication reduction compared to metformin

Q: Which of the following is not a component of Mala D?

0.15 mg desogestrel. ***0.15 mg desogestrel*** - **Mala D** is a combined oral contraceptive pill that does not contain **desogestrel**. - **Desogestrel** is a progestin primarily found in some *third-generation combined oral contraceptives* or *progestin-only pills*, not Mala D. *0.03 mg Ethinyl estradiol* - **Mala D** contains **0.03 mg of Ethinyl estradiol**, which is the estrogen component of this combined oral contraceptive. - This dosage of estrogen helps to suppress ovulation and stabilize the endometrial lining. *0.15 mg levonorgestrel* - **Mala D** contains **0.15 mg of levonorgestrel**, which is the progestin component of this combined oral contraceptive. - **Levonorgestrel** works by thickening cervical mucus, inhibiting ovulation, and altering the endometrial lining. *Iron tablets* - **Mala D** packs typically include **iron tablets** (usually 75 mg of ferrous fumarate equivalent to 60 mg elemental iron) to be taken during the placebo week. - These iron tablets are included to help prevent or treat **iron-deficiency anemia**, which can occur with menstrual blood loss.

Q: Which of the following statements about tamoxifen is false?

It cannot be used for induction of ovulation.. ***It cannot be used for induction of ovulation.*** - Tamoxifen, as a **selective estrogen receptor modulator (SERM)** with anti-estrogenic effects on the hypothalamus and pituitary, can in fact be used off-label for **ovulation induction** by increasing gonadotropin secretion. - Its anti-estrogenic action at the hypothalamus removes negative feedback, leading to increased **follicle-stimulating hormone (FSH)** release, which stimulates ovarian follicle development. *It increases the risk of venous thromboembolism.* - Tamoxifen exerts **estrogenic effects** on the coagulation system, which can lead to an increased risk of **venous thromboembolism (VTE)**, including deep vein thrombosis and pulmonary embolism. - This side effect is a significant concern, particularly in patients with other risk factors for clotting. *It is a competitive inhibitor of estrogen at receptor site* - Tamoxifen acts as a **selective estrogen receptor modulator (SERM)** by competitively binding to estrogen receptors in target tissues. - This binding prevents **endogenous estrogen** from activating the receptors, thereby exerting its anti-estrogenic effects, particularly in breast tissue. *It is a selective estrogen receptor modulator* - Tamoxifen is indeed classified as a **SERM**, meaning it has both estrogenic and anti-estrogenic effects depending on the target tissue. - It acts as an **estrogen antagonist** in breast tissue, making it effective in treating estrogen receptor-positive breast cancer, and an **estrogen agonist** in other tissues like bone and the endometrium.

Q: Which drug is preferred for the treatment of a 21-hydroxylase deficient female fetus to prevent genital virilization?

Maternal dexamethasone. ***Maternal dexamethasone*** - **Dexamethasone** is the preferred corticosteroid because it is not significantly metabolized by the placenta and can effectively reach the fetus to suppress adrenal androgen production. [2] - Its potent **glucocorticoid activity** helps to reduce the overproduction of androgens, preventing the virilization of external genitalia in affected female fetuses. [2] *Maternal cortisol* - **Cortisol** is rapidly metabolized by the placenta via **11β-hydroxysteroid dehydrogenase 2**, making it ineffective in reaching the fetal circulation in sufficient concentrations. - Therefore, it cannot adequately suppress the fetal adrenal gland's androgen production to prevent virilization. *Maternal hydrocortisone* - Similar to cortisol, **hydrocortisone** is also extensively metabolized by the placenta, reducing its bioavailability to the fetus. - It would not achieve the necessary fetal adrenal suppression to prevent **genital virilization**. [1] *Maternal methylprednisolone* - While **methylprednisolone** can cross the placenta, it is less potent than dexamethasone and may not provide sufficient suppression of fetal adrenal androgen synthesis. - **Dexamethasone** is generally considered more effective for this specific indication due to its superior placental transfer and potency.

Q: HbA1C is decreased most by?

Biguanides. ***Biguanides***- **Metformin**, the primary biguanide, is considered a first-line agent for type 2 diabetes and can significantly lower **HbA1c** by 1.0-2.0% [1].- It primarily works by decreasing hepatic **glucose production** and increasing **insulin sensitivity** in peripheral tissues [1].*Sulfonylureas*- Sulfonylureas stimulate **insulin release** from pancreatic beta cells, thereby lowering blood glucose.- They typically decrease **HbA1c** by 1.0-2.0%, similar to biguanides, but are associated with a higher risk of **hypoglycemia** and weight gain.*Thiazolidinediones*- Thiazolidinediones (TZDs) improve **insulin sensitivity** in peripheral tissues and reduce hepatic glucose production [1].- They reduce **HbA1c** by approximately 0.5-1.5% but have a slower onset of action and are associated with side effects like **fluid retention** and weight gain [1].*Acarbose*- Acarbose is an **alpha-glucosidase inhibitor** that delays the absorption of carbohydrates in the small intestine, primarily reducing postprandial glucose excursions [2].- Its effect on **HbA1c** is more modest, typically lowering it by 0.5-0.8%, making it less potent for overall long-term glucose control compared to other agents.

Q: Which of the following drugs does not cause adrenocortical suppression?

Spironolactone. ***Spironolactone*** - This drug is an **aldosterone antagonist** and a **potassium-sparing diuretic**. While it can interfere with androgen synthesis and bind to androgen and progesterone receptors, it does not directly cause generalized adrenocortical suppression of cortisol or other adrenal hormones. - Its primary actions are on the **renal tubules** to increase sodium and water excretion while retaining potassium. *Prednisone* - Prednisone is a **synthetic glucocorticoid** that, when administered exogenously, suppresses the body's natural production of cortisol by inhibiting the HPA axis (hypothalamic-pituitary-adrenal axis). - Chronic use leads to **adrenal atrophy** and decreased endogenous cortisol secretion, requiring gradual tapering to allow adrenal recovery. *Ketoconazole* - Ketoconazole is an antifungal agent that also inhibits several **cytochrome P450 enzymes** involved in steroid biosynthesis, including 11β-hydroxylase and 17α-hydroxylase. - This inhibition directly reduces the production of **cortisol** and other adrenal steroids, making it useful in conditions like Cushing's syndrome but also causing adrenocortical suppression as a side effect. *Mitotane* - Mitotane is an **adrenolytic agent** specifically used in the treatment of adrenocortical carcinoma. - It causes **selective atrophy and necrosis** of the adrenal cortex, leading to a significant reduction in cortisol and other adrenal steroid production.

Q: Which of the following statements about GnRH agonists is false?

Ganirelix is a GnRH agonist.. ***Ganirelix is a GnRH agonist.*** - **Ganirelix** is a **GnRH antagonist**, meaning it blocks the GnRH receptor and immediately suppresses gonadotropin release. - GnRH agonists initially stimulate the receptor, leading to a surge, before causing downregulation and desensitization. *Used in cases of precocious puberty.* - **GnRH agonists** are indeed used to treat **precocious puberty** by downregulating the GnRH receptors and suppressing endogenous gonadotropin-releasing hormone activity, which halts pubertal progression. - This therapy induces a temporary, reversible **hypogonadotropic hypogonadism**, effectively pausing inappropriate early puberty. *Long acting preparations can be used as nasal spray.* - Some **GnRH agonists**, like **buserelin**, are available as **nasal sprays** for long-term administration. - This route of administration allows for convenience and consistent delivery, particularly in conditions requiring chronic suppression. *They have action similar to gonadotropin releasing hormone.* - **GnRH agonists** are synthetic analogs of natural **gonadotropin-releasing hormone (GnRH)**, sharing a similar molecular structure. - They bind to and stimulate the GnRH receptors in the pituitary, initially causing increased **gonadotropin** release, followed by receptor desensitization and downregulation.

Q: Which of the following medications exhibits an incretin-like function?

Exenatide. ***Exenatide*** - **Exenatide** is a **glucagon-like peptide-1 (GLP-1) receptor agonist**, mimicking the action of naturally occurring incretin hormones. - It helps reduce blood glucose levels by **increasing glucose-dependent insulin secretion**, **reducing glucagon secretion**, and **slowing gastric emptying**. *Miglitol* - **Miglitol** belongs to the class of **alpha-glucosidase inhibitors**. - It works by delaying the digestion and absorption of carbohydrates in the small intestine, thereby reducing postprandial glucose levels. *Pioglitazone* - **Pioglitazone** is a **thiazolidinedione (TZD)** that acts as an agonist for **peroxisome proliferator-activated receptor-gamma (PPAR-γ)**. - It improves insulin sensitivity in peripheral tissues and the liver, leading to increased glucose uptake and utilization. *Repaglinide* - **Repaglinide** is a **meglitinide**, a class of **insulin secretagogues**. - It stimulates insulin release from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels.

Question 1

What is the mechanism of action of sulfonylureas?

Accepted Answer

K ATP channel blocker

Answer

Sodium channel blocker

Answer

Calcium channel blocker

Answer

Chloride channel blocker

Question 2

Which of the following drugs is known to reduce the risk of both macrovascular and microvascular complications of diabetes mellitus?

Accepted Answer

Metformin

Answer

Acarbose

Answer

Repaglinide

Answer

Sitagliptin

Question 3

Which of the following is not a component of Mala D?

Accepted Answer

0.15 mg desogestrel

Answer

0.03 mg Ethinyl estradiol

Answer

0.15 mg levonorgestrel

Answer

Iron tablets

Question 4

Which of the following statements about tamoxifen is false?

Accepted Answer

It cannot be used for induction of ovulation.

Answer

It increases the risk of venous thromboembolism.

Answer

It is a competitive inhibitor of estrogen at receptor site

Answer

It is a selective estrogen receptor modulator

Question 5

Which drug is preferred for the treatment of a 21-hydroxylase deficient female fetus to prevent genital virilization?

Accepted Answer

Maternal dexamethasone

Answer

Maternal hydrocortisone

Answer

Maternal methylprednisolone

Answer

Maternal cortisol

Question 6

HbA1C is decreased most by?

Accepted Answer

Biguanides

Answer

Thiazolidinediones

Answer

Sulfonylureas

Answer

Acarbose

Question 7

Which of the following drugs does not cause adrenocortical suppression?

Accepted Answer

Spironolactone

Answer

Prednisone

Answer

Ketoconazole

Answer

Mitotane

Question 8

What is a special feature of glargine insulin?

Accepted Answer

It provides a long duration of action with a smooth, peakless effect.

Answer

It is suitable for once daily administration.

Answer

It is stable at physiological pH.

Answer

It is primarily used for basal insulin control.

Question 9

Which of the following statements about GnRH agonists is false?

Accepted Answer

Ganirelix is a GnRH agonist.

Answer

Long acting preparations can be used as nasal spray.

Answer

Used in cases of precocious puberty.

Answer

They have action similar to gonadotropin releasing hormone.

Question 10

Which of the following medications exhibits an incretin-like function?

Accepted Answer

Exenatide

Answer

Repaglinide

Answer

Pioglitazone

Answer

Miglitol

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?